Furthermore, we performed Kaplan‒Meier survival analysis on glioma patient datasets from TCGA and CGGA, which revealed that high SOX9 expression is correlated with poor clinical outcomes across multiple glioma cohorts (CGGA693-primary glioma, CGGA693-recurrent glioma, TCGA-LGG, and TCGA-GBM). This evidence concerns the gene SOX9 and central nervous system cancer.